Format

Send to

Choose Destination
Ann Surg Oncol. 2017 Apr;24(4):974-982. doi: 10.1245/s10434-016-5657-6. Epub 2016 Nov 7.

Ultimate Clinical Outcomes of Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential.

Shin R1,2, Chai YJ1,2, Park JW2,3,4, Chang MS5, Bae JM5, Kim MJ6, Park BK6, Park KJ2,3,4, Jeong SY7,8,9.

Author information

1
Department of Surgery, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul, Korea.
2
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
3
Cancer Research Institute, Seoul National University, Seoul, Korea.
4
Colorectal Cancer Center, Seoul National University Cancer Hospital, Seoul, Korea.
5
Department of Pathology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
6
Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, Gyeonggi, Korea.
7
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. syjeong@snu.ac.kr.
8
Cancer Research Institute, Seoul National University, Seoul, Korea. syjeong@snu.ac.kr.
9
Colorectal Cancer Center, Seoul National University Cancer Hospital, Seoul, Korea. syjeong@snu.ac.kr.

Abstract

BACKGROUND:

The clinical outcome of appendiceal mucinous neoplasm (AMN) is not well understood. This study aimed to compare the long-term outcome for the uncertain malignant potential (UMP) subtype of AMNs with those of the mucinous adenoma (MA) and mucinous adenocarcinoma (MAC) subtypes.

METHODS:

In this study, AMNs were classified into three groups (MA, UMP, and MAC), and clinical characteristics, overall survival (OS), and progression-free survival (PFS) were compared among the three groups.

RESULTS:

The study included 65 AMN patients (26 MA, 20 UMP, and 19 MAC patients). The median follow-up period was 87 months (range 0.3-311.0) months. The symptoms at diagnosis and the presence of pseudomyxoma peritonei were more common in the MAC group than in the MA group (P = 0.012) or the UMP group (P < 0.001). The 5-year OS rates were 95.5% for the MA group, 93.8% for the UMP group, and 78.3% for the MAC group (P < 0.001), and the 5-year PFS rates were 95.2% for the MA group, 95% for the UMP group, and 36.8% for the MAC group (P < 0.001). Thus, OS and PFS did not differ significantly in the MA and UMP groups (P = 0.884 and 0.345, respectively). In contrast, the OS and PFS of the MAC group were worse than in the MA group (P = 0.017 and <0.001, respectively) or the UMP group (P < 0.001 and 0.001, respectively).

CONCLUSIONS:

The long-term outcome for UMP tumors is similar to that for MA tumors and significantly better than for MAC tumors.

PMID:
27822629
DOI:
10.1245/s10434-016-5657-6
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center